Spots Global Cancer Trial Database for BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT

Official Title: Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation

Study ID: NCT02670252

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation

Busulfan

Total Body Irradiation

Acute Lymphocytic Leukemia

Interventions

Busulfan (BU)

Cyclophosphamide (CY)

Total Body Irradiation (TBI)

Study Description

Brief Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) appears to be an efficient tool to cure standard-risk acute lymphocytic leukemia (ALL) in first CR (CR1) but the choice between BU-based or TBI-based conditioning regimens still remains controversial. In this study, the safety and efficacy of BUCY and TBICY myeloablative conditioning regimens in patients undergoing allo-HSCT for ALL in CR1 are evaluated.

Detailed Description: Allo-HSCT appears to be an efficient tool to cure standard-risk ALL in CR1. The conditioning regimen with BUCY or TBICY is considered as the standard myeloablative regimen for ALL in CR1, but the choice between BU-based or TBI-based conditioning regimen still remains controversial.In order to analyze the impact of conditioning regimen on long-term survival and relapse, in this study, the safety and efficacy of BUCY and TBICY myeloablative conditioning regimens in patients undergoing allo-HSCT for ALL in CR1 are evaluated.